A 52-year-old Indian woman is found incidentally to have a 3.5 cm left renal mass on contrast-enhanced CT done for abdominal pain. The mass is homogeneous, well-circumscribed, and shows enhancement in the arterial phase consistent with RCC. She is fit for surgery with no comorbidities. Staging workup (chest CT, bone scan) shows no metastases. What is the most appropriate next step in management?

Explanation

## Clinical Presentation This patient has a **small, localized renal cell carcinoma (T1a, <4 cm)** with: - Tumor size 3.5 cm (well below 4 cm threshold) - No evidence of metastatic disease (M0) - Good performance status and normal renal function - No contraindications to nephron-sparing surgery ## Nephron-Sparing Surgery: The Standard of Care for T1a RCC **Key Point:** Partial nephrectomy (nephron-sparing surgery) is the gold standard for T1a tumors (<4 cm) in patients with normal contralateral kidney function [cite:Robbins 10e Ch 20]. **High-Yield:** Partial nephrectomy achieves equivalent oncologic outcomes to radical nephrectomy while preserving renal parenchyma and reducing long-term cardiovascular and renal morbidity. ## Comparison of Management Options for T1a RCC | Modality | Indication | Outcome | Limitation | |----------|-----------|---------|------------| | **Partial nephrectomy** | T1a, fit patient, normal contralateral kidney | Gold standard; equivalent OS/DFS to radical nephrectomy | Requires surgical expertise | | Active surveillance | Elderly, unfit, or patient preference | Acceptable for very small (<2 cm) or slow-growing tumors | Risk of progression; requires close imaging | | Ablation (RFA/cryo) | T1a, unfit for surgery, or solitary kidney | Local control ~90–95% | Higher recurrence than surgery; limited for tumors >4 cm | | Adjuvant TKI | High-risk resected RCC (T3–T4, N+) | Modest DFS benefit in selected cases | Not standard for T1a; no OS benefit demonstrated | ## Why Partial Nephrectomy Is Correct 1. **Tumor size** — At 3.5 cm, this is ideal for nephron-sparing approach. 2. **Oncologic equivalence** — Partial nephrectomy achieves the same cancer-free survival as radical nephrectomy for T1a tumors. 3. **Functional benefit** — Preserves renal mass, reducing long-term CKD risk and cardiovascular events. 4. **Fit patient** — No contraindications to open or robot-assisted partial nephrectomy. **Clinical Pearl:** Modern series show that partial nephrectomy can be performed open, laparoscopic, or robot-assisted with low morbidity and excellent oncologic outcomes for T1a tumors. ## Why Other Options Are Incorrect 1. **Active surveillance** — Acceptable only for very small tumors (<2 cm) or in elderly/unfit patients who decline intervention. A 3.5 cm tumor in a fit patient warrants definitive treatment. Surveillance risks progression and metastasis. 2. **Radiofrequency ablation** — While acceptable for T1a tumors in unfit patients, it is not first-line in a fit patient. Ablation has higher local recurrence rates (~5–10%) compared to surgery (~1–2%) and is less suitable for tumors approaching 4 cm. 3. **Adjuvant sunitinib** — Not indicated for T1a disease. Adjuvant TKI is reserved for high-risk resected RCC (T3–T4, N+, or grade 4) and has not shown OS benefit in T1a patients. Giving systemic therapy to a patient with completely resected low-risk disease increases toxicity without proven benefit.